Clinical Trial Update: Gemcitabine Plus Erlotinib Versus Erlotinib Plus Gemcitabine Plus Oxaliplatin, in Pancreatic Cancer [Phase 2]

View source ↗

Summary

This Phase 2 trial in pancreatic cancer comparing Gemcitabine plus Erlotinib versus Erlotinib plus Gemcitabine plus Oxaliplatin was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Eloxatin (oxaliplatin)
• Gemzar (gemcitabine)
• Tarceva (erlotinib)

Snippet

Sponsor: Hellenic Oncology Research Group | Conditions: Pancreatic Cancer | Phase 2 | Status: TERMINATED